Amlodipine treatment decreases plasma and carotid artery tissue levels of endothelin-1 in atherosclerotic rabbits

Pathophysiology

Volumn 18, Issue 2, 2011, Pages 137-142

  Rashidi, Bahman ^a   Mohammadi, Mostafa ^b   Mirzaei, Fariba ^b   Badalzadeh, Reza ^c   Reisi, Parham ^d  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

^d ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Amlodipine; Atherosclerosis; Endothelin 1; Rabbit

Indexed keywords

AMLODIPINE; CHOLESTEROL; ENDOTHELIN 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG ACTIVITY; ENDOTHELIUM CELL; EXPERIMENTAL RABBIT; LIPID ANALYSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TISSUE LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79952042417     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pathophys.2010.05.003     Document Type: Article

References (27)

1. Barton M. Endothelial dysfunction and atherosclerosis: endothelin receptor antagonists as novel therapeutics. Curr. Hypertens. Rep. 2000, 2(1):84-91.
2. Barton M., Haudenschild C.C., D'Uscio L.V., Shaw S., Munter K., Luscher T.F. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 1998, 95(24):14367-14372.
3. Barton M., Traupe T., Haudenschild C.C. Endothelin, hypercholesterolemia and atherosclerosis. Coron. Artery Dis. 2003, 14(7):477-490.
4. Bohm F., Johansson B.L., Hedin U., Alving K., Pernow J. Enhanced vasoconstrictor effect of big endothelin-1 in patients with atherosclerosis: relation to conversion to endothelin-1. Atherosclerosis 2002, 160(1):215-222.
5. Catapano A.L. Calcium antagonists and atherosclerosis. Experimental evidence. Eur. Heart J. 1997, 18(Suppl. A):A80-A86.
6. Chen L., Haught W.H., Yang B., Saldeen T.G., Parathasarathy S., Mehta J.L. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J. Am. Coll. Cardiol. 1997, 30(2):569-575.
7. Dashwood M.R., Tsui J.C. Endothelin-1 and atherosclerosis: potential complications associated with endothelin-receptor blockade. Atherosclerosis 2002, 160(2):297-304.
8. Henry P.D. Atherogenesis, calcium and calcium antagonists. Am. J. Cardiol. 1990, 66(21):3I-6I.
9. Ihling C., Gobel H.R., Lippoldt A., Wessels S., Paul M., Schaefer H.E., Zeiher A.M. Endothelin-1-like immunoreactivity in human atherosclerotic coronary tissue: a detailed analysis of the cellular distribution of endothelin-1. J. Pathol. 1996, 179(3):303-308.
10. Jen C.J., Chan H.P., Chen H.I. Chronic exercise improves endothelial calcium signaling and vasodilatation in hypercholesterolemic rabbit femoral artery. Arterioscler. Thromb. Vasc. Biol. 2002, 22(7):1219-1224.
11. Jukema J.W., Zwinderman A.H., van Boven A.J., Reiber J.H., Van der L.A., Lie K.I., Bruschke A.V. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group. Arterioscler. Thromb. Vasc. Biol. 1996, 16(3):425-430.
12. Kowala M.C. The role of endothelin in the pathogenesis of atherosclerosis. Adv. Pharmacol. 1997, 37:299-318.
13. Laroia S.T., Ganti A.K., Laroia A.T., Tendulkar K.K. Endothelium and the lipid metabolism: the current understanding. Int. J. Cardiol. 2003, 88(1):1-9.
14. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995, 91(11):2844-2850.
15. Mason R.P. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis 2002, 165(2):191-199.
16. Meraji S., Abuja P.M., Hayn M., Kostner G.M., Morris R., Oraii S., Tatzber F., Wonisch W., Zechner R., Gey K.F. Relationship between classic risk factors, plasma antioxidants and indicators of oxidant stress in angina pectoris (AP) in Tehran. Atherosclerosis 2000, 150(2):403-412.
17. Minami S, Yamano S., Yamamoto Y., Sasaki R., Nakashima T., Takaoka M., Hashimoto T. Associations of plasma endothelin concentration with carotid atherosclerosis and asymptomatic cerebrovascular lesions in patients with essential hypertension. Hypertens. Res. 2001, 24(6):663-670.
18. Mohammadi M., Mirzaei F., Badalzadeh R. Effect of amlodipine on blood and aortic tissue concentration of endothelin in male rabbits receiving atherogenic diet. Indian J. Pharmacol. 2007, 39(6):276-280.
19. Nayler W.G. Review of preclinical data of calcium channel blockers and atherosclerosis. J. Cardiovasc. Pharmacol. 1999, 33(Suppl. 2):S7-S11.
20. Niemann B., Rohrbach S., Catar R.A., Muller G., Barton M., Morawietz H. Native and oxidized low-density lipoproteins stimulate endothelin-converting enzyme-1 expression in human endothelial cells. Biochem. Biophys. Res. Commun. 2005, 334(3):747-753.
21. Okada K., Nishida Y., Murakami H., Sugimoto I., Kosaka H., Morita H., Yamashita C., Okada M. Role of endogenous endothelin in the development of graft arteriosclerosis in rat cardiac allografts-antiproliferative effects of bosentan, a nonselective endothelin receptor antagonist. Circulation 1998, 97(23):2346-2351.
22. Pitt B, Byington R.P., Furberg C.D., Hunninghake D.B., Mancini G.B., Miller M.E., Riley W. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000, 102(13):1503-1510.
23. Properzi G., Francavilla F., Bellini C., D'Abrizio P., Mangiacotti B., Ferri C., Spartera C., Santucci A., Francavilla S. Blood endothelin-1 levels before and after carotid endoarterectomy for atherosclerotic stenosis. Atherosclerosis 2001, 154(1):137-140.
24. Schiffrin E.L. Role of endothelin-1 in hypertension and vascular disease. Am. J. Hypertens. 2001, 14(6 (Pt 2)):83S-89S.
25. Tulenko T.N., Laury-Kleintop L., Walter M.F., Mason R.P. Cholesterol, calcium and atherosclerosis: is there a role for calcium channel blockers in atheroprotection?. Int. J. Cardiol. 1997, 62(Suppl. 2):S55-S66.
26. Waters D., Lesperance J., Francetich M., Causey D., Theroux P., Chiang Y.K., Hudon G., Lemarbre L., Reitman M., Joyal M. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990, 82(6):1940-1953.
27. Zeiher A.M., Goebel H., Schachinger V., Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation 1995, 91(4):941-947.